Quince provides EryDel historical financials; FY2022 loss of €12.5M

Quince Therapeutics, Inc.

EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.
As of Dec 2022, EryDel cash €1.3M, negative equity €16.5M; operating cash flow used €11.3M.
Quince had $83.2M cash at Sep 30, 2023, expected to fund EryDex Phase 3 trial into at least 2026.
Acquisition adds EryDel's Red Cell Loader platform and Phase 3 therapy for Ataxia-Telangiectasia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.